Posters
Prevalence of ocular comorbidity in eyes undergoing cataract surgery
Poster Details
First Author: M.Vieversyte LITHUANIA
Co Author(s): A. Pajeda L. Vaicaite A. Varoniukaite D. Zaliuniene L. Kuzmiene
Abstract Details
Purpose:
To describe prevalence of ocular comorbidity and preoperative visual acuity in eyes undergoing cataract surgery
Setting:
Hospital of Lithuanian Health Sciences University Kauno Klinikos (Tertiary unit)
Methods:
Restrospective data of 502 eyes from 422 patients undergoing cataract surgery between January 1st 2017 and March 1st 2017 were collected . Demographic data, ocular comorbidity (OC), preoperative best corrected visual acuity were evaluated. Patients were divided into age groups : <60 years (y) ; [61-70]y; [71-80]y; >81y. Preoperative best corrected distance visual acuity (BCDVA) was evaluated and divided into groups as follows: �â��¤0,1, (0,1-0,4], �â��¥0,5. Comparisons were made by using Chi square tests for qualitative variables. p < 0.05 level was considered to be statistically significant. Basic characteristics are presented in percentage, means �Â�± standart deviation.
Results:
502 eyes were included into the study: 35.5% men, 64.5% women. Mean age was 71,68 �Â�± 9,77y. 51,4% of cases had no OC. OC was diagnosed in 48,6% of cases: glaucoma in 31.3%, age-related macular degeneration (AMD) 10.8%, diabetic retinopathy 4.8%, other diseases 11,8%. Eyes with one ocular OC accounted for 39%, with 2-9.2% and with 3-0.4%. The rate of OC increased with age. Glaucoma significantly increased in 71-80y group, while AMD in 71-80y and older. BCDVA groups before surgery: <0,1�â��47,81%, (0,1-0,4]�â��44,62%, �â��¥0,5 �â��7,57%. There was no signifficant difference in preoperative BCDVA between eyes with and without OC.
Conclusions:
Patients scheduled for cataract surgery were mostly older than 70 years with high rate of ocular comorbidity which increased with age, predominant disease �� glaucoma. Preoperative best corrected distance visual acuity did not differ significantly between the groups with or without other eye diseases.
Financial Disclosure:
NONE
